Monday, January 27, 2014
is developing a recombinant version of the HIV envelope protein that, when used
on its own, can function as a therapeutic to reestablish immune tolerance in
autoimmune diseases. Preclinical studies showed the therapeutic can prevent
graft-versus-host disease without compromising the immune system.
TCF founder and CEO Olaf
Althaus noted the human immune system has a delicate balance between effector T
cells, which stimulate immune reactions, and regulatory T cells (Tregs), which
suppress T cell-mediated responses and maintain immune tolerance.